The final study sample contained 13 335 unique patients with OUD (mean [SD] age, 33.1 [13.1] years; 5884 female participants [44.1%]; mean observation time, 627.6 days; 8 424 214 person-days of observation time) who received OUD medications and had at least 1 alcohol-related acute event. Table 1 summarizes descriptive statistics at the individual participant level, with stratification by the presence of recent AUD claims. In total, 19.6% of the sample (2615 individuals) had claims for more than 1 event. Of all participants, 6299 (47.2%) received buprenorphine in the year before and after the index event; in comparison, 667 (5.0%) received methadone, 1096 (8.2%) received extended-release naltrexone, and 3236 (24.3%) received oral naltrexone. Although all participants had received OUD medication during insurance enrollment, 2037 (15.3%) did not receive OUD medication during the 1 year before and after index event that constituted our study’s observation window.
